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Abstract Transcription factor Ets-1 expressed in endothelial
cells promotes angiogenesis. Here, we transiently overexpressed
Ets-1 in human umbilical vein endothelial cells (HUVECs) and
comprehensively searched for potential downstream targets of
Ets-1 by cDNA microarray analysis. The expression of several
angiogenesis-related genes including neuropilin-1 was augmented
by the overexpression of Ets-1. Quantitative real-time RT-PCR
and Western blotting confirmed the increase in the levels of
neuropilin-1 mRNA and protein. In contrast, dominant negative
ets-1 decreased the levels of neuropilin-1 mRNA and protein.
These results indicate that neuropilin-1 is a downstream target of
Ets-1 in HUVECs. ß 2001 Federation of European Biochem-
ical Societies. Published by Elsevier Science B.V. All rights
reserved.
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1. Introduction
Angiogenesis, the formation of neo-vessels from pre-exist-
ing ones, occurs in a wide range of physiological as well as
pathological states, including embryogenesis, wound healing,
diabetic retinopathy, rheumatoid arthritis, and solid tumors.
Angiogenesis is regulated by the balance between angiogenic
factors and angiogenesis inhibitors. Numerous molecules have
been reported to regulate angiogenesis. Among them, vascular
endothelial growth factor (VEGF) is the most important an-
giogenic factor. VEGF binds to two signal-transducing recep-
tor-type tyrosine kinase, Flt-1 (VEGFR-1) and KDR/Flk-1
(VEGFR-2), and stimulates protease synthesis, migration
and proliferation of endothelial cells (ECs) [1]. More recently,
the semaphorin receptor neuropilin-1 was identi¢ed as the
binding site of VEGF on the surface of ECs [2]. Neuropilin-
1 is thought to accumulate VEGF on the cell surface and
transfer it to signal-transducing VEGF receptors.
ECs express various genes during angiogenesis, and thus an
understanding of the transcriptional control of these genes in
ECs is important. Ets-1 is a prototype of the Ets family of
transcription factors. Ets-1 is expressed in ECs during angio-
gensis or re-endothelialization after denuding injury [3,4]. An-
giogenic factors including VEGF are potent inducers of Ets-1
in ECs [3,5,6]. In contrast, TGF-L attenuates the transactiva-
tion activity of Ets-1 by inhibiting the binding of Ets to DNA
via Ets binding motif [7]. Ets-1 positively regulates angiogen-
esis [3,8], and the elimination of the e¡ect of Ets-1 by a dom-
inant negative molecule inhibits angiogenesis in vivo [9]. The
genes for several molecules including uPA, MMP-1, MMP-3,
MMP-9, integrin L3, and VE-cadherin are reported to be
downstream targets of Ets-1 in ECs [3,8,10]. Moreover, endo-
thelium-speci¢c, receptor-type tyrosine kinase such as Flt-1,
KDR, TIE-1 and TIE-2 contain the Ets binding motif in their
promoter/enhancer regions, and the Ets family transcription
factors are suggested to stimulate their promoter activities
[11^14].
To further clarify the downstream targets of Ets-1 in ECs,
we transiently overexpressed Ets-1 in human umbilical vein
endothelial cells (HUVECs) with an adenovirus vector encod-
ing the wild-type ets-1 gene (Adets-1) and comprehensively
searched for potential downstream targets by cDNA micro-
array analysis. Our analysis revealed that neuropilin-1 is yet
another downstream target of Ets-1 in ECs.
2. Materials and methods
2.1. Cell culture
HUVECs were obtained from Kurabo (Osaka, Japan), and cultured
on type-I collagen-coated dishes (Iwaki, Tokyo, Japan) in endothelial
basal medium (EBM) containing EC growth supplements (Clonetics
Corp., Walkersville, MD, USA) and 10% fetal bovine serum (FBS,
JRH Biosciences, San Antonio, TX, USA).
2.2. Adenovirus-mediated gene transfer
Adenovirus vectors encoding wild-type ets-1 (Adets-1), transdomi-
nant mutants ets-1 (AdTMets-1), and a control adenovirus (Adnull)
were described elsewhere [9,15]. HUVECs were infected with the ad-
enovirus vectors at a multiplicity of infection (m.o.i.) of various val-
ues. Adenoviral infection was carried out in agitated serum-free M199
(Nissui, Tokyo, Japan) for 1 h at 37‡C, and the medium was then
changed to M199 containing 20% FBS, after which the cells were
further incubated for the desired periods of time.
2.3. cDNA microarray analysis
Total RNA was prepared from HUVECs infected with Adets-1 or
Adnull by use of ISOGEN (Nippongene, Toyama, Japan), and
poly(A)+ RNA was puri¢ed from the total RNA by using an Oligo-
tex-dT30 Gsuperf mRNA puri¢cation kit (Takara Shuzo Co., Ltd,
Shiga, Japan). cDNA probe synthesis, hybridization with a human
UniGEM V cDNA microarray, and signal analysis were conducted
by Genome Systems (St. Louis, MO, USA). Clones with a Cy3 signal/
Cy5 balanced signal ratio larger than 2.5 were considered to be in-
duced.
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2.4. Quantitative RT-PCR analysis
Total RNA samples were prepared from subcon£uent cultures of
HUVECs infected with Adets-1, AdTMets-1 or Adnull by use of
ISOGEN. First-strand cDNAs were generated with a 1st Strand
cDNA Synthesis kit for RT-PCR (Roche Diagnostics, Mannheim,
Germany). Quantitative RT-PCR was conducted with a LightCycler1
and SyberGreen System (Roche Diagnostics, Mannheim, Germany)
according to the manufacturer’s instruction. The human neuropilin-1
primer set and the hybridization probes used were the following: sense
5P-CCAAGCTTTTCTCAGGAGCTTCA-3P and antisense 5P-TTTC-
CGTGAACTCTCCTGTA-3P.
2.5. Western blot analysis
Cells were extracted with modi¢ed RIPA bu¡er (2 mM sodium
orthovanadate, 50 mM NaF, 20 mM HEPES, 150 mM NaCl, 1.5
mM MgCl2, 5 mM sodium pyrophosphate, 10% glycerol, 0.2% Triton
X-100, 5 mM EDTA, 1 mM PMSF, 10 Wg/ml leupeptin, and 10 Wg/ml
aprotinin). Equal amounts of samples were applied for SDS^PAGE
under reducing conditions and transferred to a nitrocellulose mem-
brane (Hybond ECL, Amersham, Buckinghamshire, England). The
membrane was incubated with rabbit polyclonal anti-human neuro-
pilin-1 antibody (Santa Cruz Biotechnology, Inc., CA, USA) as a
primary antibody according to the manufacturer’s instructions. The
signal was visualized by using HRP-conjugated secondary antibodies
and enhanced chemiluminescence (ECL, Amersham, Buckingham-
shire, England) with an LAS-1000 image analyzer (Fuji, Tokyo, Ja-
pan).
3. Results
To explore the downstream targets of Ets-1 in ECs, we
infected HUVECs with Adets-1 and compared the expression
pro¢le with that of HUVECs infected with Adnull. After a 48-
h incubation, we analyzed the expression pro¢le with a cDNA
microarray. The scatter plot of expression in Adets-1-infected
HUVECs versus that in Adnull-infected ones is shown in Fig.
1. A number of genes were modulated in their expression.
Among the 9375 human genes in the microarray, 110 of
them were augmented in their expression more than 2.5 fold.
Twenty-two of the known angiogenesis-related genes in the
present microarray were selected and their relative expression
are shown in Table 1. It appeared that the expression of seven
genes was augmented more than 2.5 folds by the exogenously
expressed Ets-1 in HUVECs. Of these, MMP-1 is the only
molecule that has already been recognized as a downstream
target of Ets-1 in ECs. The other six genes, including neuro-
pilin-1, have not been previously recognized as downstream
targets of Ets-1.
Neuropilin-1 is the binding site of VEGF on the surface of
ECs, and is thought to modulate the e¡ect of VEGF on ECs.
However, transcriptional regulation of its expression is ob-
scure at the moment. Therefore, we clari¢ed the expression
of neuropilin-1 by real-time RT-PCR analysis. A time course
experiment revealed that an increase in the level of neuropilin-
1 mRNA was evident as early as 24 h after the infection (Fig.
2A). This increase was detected at an m.o.i. as low as 10, and
was maximal at an m.o.i. of 100 (Fig. 2B). To further prove
the involvement of endogenous Ets-1 in the expression of
neuropilin-1, we used the adenovirus encoding transdominant
mutant Ets-1 (AdTMets-1), which acts as a dominant negative
Fig. 1. Expression pro¢le of HUVEC genes analyzed with a cDNA
microarray. HUVECs were infected with Adnull or Adets-1. After a
48-h incubation, poly(A)+ RNA was obtained. Microarray analysis
was performed as described in Section 2. The scatter plot of expres-
sion in Adets-1-infected HUVECs versus that in Adnull-infected
ones is shown.
Fig. 2. Time course and m.o.i. dependency of Adets-1 on the expression of neuropilin-1 mRNA in HUVECs. A: HUVECs were infected with
200 m.o.i. of Adnull or Adets-1. At the indicated time points, total RNA was obtained, and real-time RT-PCR was then performed. B: HU-
VECs were infected with the indicated m.o.i. of Adnull or Adets-1. After a 48-h incubation, total RNA was obtained, and real-time RT-PCR
was performed. The expression of neuropilin-1 in Adets-1-infected HUVECs was standardized with that in Adnull-infected HUVECs.
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over Ets-1. The real-time RT-PCR analysis showed that AdT-
Mets-1 decreased the level of neuropilin-1 mRNA in the same
experiment where Adets-1 increased it (Fig. 3A). Moreover,
AdTMets-1 decreased the protein level of neuropilin-1 as well
(Fig. 3B).
4. Discussion
The cDNA microarray analysis revealed that Ets-1 aug-
mented the expression of seven angiogenesis-related genes in
HUVECs. Among them, six genes have not been previously
recognized as downstream targets of Ets-1. We further clari-
¢ed one of those genes, namely, neuropilin-1. Neuropilin-1
was initially identi¢ed as a membrane protein that is expressed
in developing neurons, and it was found to function as a
receptor for the class 3 semaphorins, which produce inhibitory
axon guidance signals [16]. More recently, neuropilin-1 was
shown to be expressed in ECs and to function as a co-receptor
for VEGF165 [2] and several other members of the VEGF
family [17,18]. The neuropilin-1 mutant mouse embryos ex-
hibited severe abnormalities in their nervous as well as car-
diovascular system [19,20], indicating that neuropilin-1 plays
important roles in embryonic nervous tissue and vessel for-
mation. Neuropilin-1 is thought to be involved in postnatal
angiogenesis as well, since the expression of neuropilin-1 cor-
relates with that of VEGFR2 in the tissues of rheumatoid
arthritis and diabetic proliferative retinopathy [21,22].
Although neuropilin-1 is recognized as an important medi-
ator of angiogenesis, information on the transcriptional regu-
lation of the neuropilin-1 gene in ECs is limited. Targeted
deletion of the dHAND gene in mice results in severe defects
of embryonic and yolk sac vascular development and the
downregulation of neuropilin-1 in ECs [23]. However, since
the expression of dHAND is restricted to smooth muscle cells,
the downregulation of neuropilin-1 in ECs does not directly
relate to targeted deletion of the dHAND gene. Our present
results suggest for the ¢rst time that neuropilin-1 is the down-
stream target of Ets-1 in ECs. Tumor necrosis factor-K (TNF-
K) was shown to induce the expression of both neuropilin-1
[24] and Ets-1 [25] in ECs. Thus, TNF-K may induces the
expression of neuropilin-1 via the induction of Ets-1. Further
study is required to clarify the promoter region of neuropilin-
1 gene to determine whether or not an Ets binding site(s)
exists and functions there.
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